Figure 4
- ID
- ZDB-FIG-200511-32
- Publication
- Volpatti et al., 2020 - Identification of drug modifiers for RYR1 related myopathy using a multi-species discovery pipeline
- Other Figures
-
- Figure 1
- Figure 2
- Figure 2-figure supplement 1
- Figure 2-figure supplement 2
- Figure 2-figure supplement 3
- Figure 2-figure supplement 4
- Figure 2-figure supplement 5
- Figure 3
- Figure 3-figure supplement 1
- Figure 4
- Figure 4-figure supplement 1
- Figure 4-figure supplement 2
- Figure 4-figure supplement 3
- Figure 5
- Figure 5-figure supplement 1
- Figure 5-figure supplement 2
- Figure 5-figure supplement 3
- Figure 5-figure supplement 4
- All Figure Page
- Back to All Figure Page
Compared to the average speed of DMSO WT controls, treatment with (A) SB239063 and (B) PH-797804 reduced the average speed of WT siblings while the expected decrease in movement speed in treated ryr1b was not observed. The difference in average speed of ryr1b+p38 inhibitor compared to WT controls (i.e. WT siblings+DMSO vehicle) is higher than expected given the effects of genotype and chemical alone, indicative of a positive chemical-genetic interaction. Chemical-genetic interactions were not observed for p38 inhibitors (C) SB203580 and (D) SB202190. Data are presented as mean ± SEM movement speed (mm/s) normalized to DMSO-treated WT siblings for n = 2 independent experiments. Statistical analysis by two-way ANOVA followed by Tukey’s multiple comparisons post-test. *p<0.05, **p<0.01, ***p<0.001; Sample size n = 19 or 20 for each treatment group in a set. |
| Fish: | |
|---|---|
| Conditions: | |
| Observed In: | |
| Stage: | Day 4 |